When you have cancer, you want the best doctors and effective therapies tailored just for you. At Mayo Clinic we have more than 4,000 world class physicians in every medical specialty dedicated to working together to chart the quickest path to healing. When it comes to cancer research, Mayo Clinic has the broadest, most comprehensive oncolytic virotherapy program in the US.
Thanks to benefactors, Mayo Clinic Cancer Center (MCCC) is making great strides in cancer research. Our teams work day and night caring for patients and researching revolutionary ways to treat and prevent cancer in its many forms. Because when you or a loved one has cancer, we know you want us to fight it with everything we have. …show more content…
Your gift will enable investigators to continue this revolutionary research and advance to clinical testing.
Matching? Fund? Name plate
[Inside right]
[pull out, headline style]
Mayo Clinic Researches discovered the use of combining a sodium iodide symporter (NIS) molecule with a virus to kill cancer cells.
In 2004, Mayo Clinic Researchers coin the treatment term radiovirotherapy after their discovery of administering a radioactive form of iodine (either iodine-123 or iodine-131) with a virus to combat cancer.
Mayo Clinic First to show virotherapy is promising against multiple myeloma.
The FDA approved Mayo Clinic as the first institution in the United States to manufacture and administer Choline C-11 Injection. An imaging agent which can help locate cancer when PSA levels are at least half of what current imaging techniques can detect.
Researchers at Mayo Clinic Florida campus are first to link the enzyme PRSS3 to prostate cancer and have also developed a compound that inhibits the ability of this molecule to promote the metastatic spread of the cancer.
Oncologic Virotherapy for Prostate …show more content…
Under the leadership of Evanthia Galanis, M.D., The Gene and Virus Therapy Program of the Mayo Clinic Cancer Center focuses on developing new gene-delivery systems and gene- and virus-based therapies for cancer treatment.
The idea of using a virus to fight cancer is not new. Animal studies using viruses date back to the 1940s, but the technology and the basic facilities and equipment necessary to manufacture a gene or virus therapy pure enough to meet the Food and Drug Administration’s (FDA) standards for use in humans has always been the challenge.
In 1998, Mayo Clinic made a commitment to advance its program of gene and virus therapy by recruiting hematologist and scientist Stephen Russell, M.D., Ph.D., from Cambridge University in England to direct Mayo’s Molecular Medicine Program. The Molecular Medicine Program at Mayo has grown in expertise and infrastructure to become one of the very few places where clinical-grade reengineered viruses and viral vectors can be manufactured all the way through to patient